Transplant Ineligible | List of Frontiers open access articles

Original Research

Published on 01 Mar 2021

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma

in Drugs Outcomes Research and Policies

Yaohua Cao
Lina Zhao
Tiantian Zhang
Weiling Cao

Frontiers in Pharmacology

doi 10.3389/fphar.2021.608685

6,958 views
9 citations

Review

Published on 08 Apr 2025

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias

in Cancer Immunity and Immunotherapy

Heather T. Morgan
Benjamin A. Derman
Hong Ma
Shaji K. Kumar

Frontiers in Immunology

doi 10.3389/fimmu.2025.1558275

6,048 views
4 citations

Review

Published on 11 May 2022

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

in Hematologic Malignancies

Luca Bertamini
Giuseppe Bertuglia
Stefania Oliva

Frontiers in Oncology

doi 10.3389/fonc.2022.844779

11,030 views
26 citations

Systematic Review

Published on 25 Jan 2024

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

in Hematologic Malignancies

Wenjiao Tang
Li Zhang
Yuhuan Zheng
Ling Pan
Ting Niu

Frontiers in Oncology

doi 10.3389/fonc.2024.1286029

5,804 views
9 citations

Systematic Review

Published on 06 Jan 2026

The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials

in Cancer Immunity and Immunotherapy

Bin Hu
Dan Fang
Ling Jiang
Tianqi Li
Kexia Chen
Jinxia Cao
Jun Wang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1744165

1,469 views

Original Research

Published on 09 May 2025

Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)

in Hematologic Malignancies

Ayman Alhejazi
Ahmad Alhuraiji
Abdulnaser Nourallah
Abdulrahman Alshehri
Binyam Usman
Ghada ElGohary
Hafiz Malhan
Ibraheem Motabi
Khalil Al Farsi
Mohammed Alshuaibi

Frontiers in Oncology

doi 10.3389/fonc.2025.1547138

4,294 views

Articles

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials

Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)